Follistatin 344 vs IGF-1

Binds and neutralizes myostatin (GDF-8) and activin; removes the natural brake on muscle growth allowing supraphysiological hypertrophy

Follistatin-344 is the predominant endogenous isoform of follistatin, a glycoprotein that binds and neutralizes the TGF-β superfamily members activin A and myostatin, preventing their engagement with skeletal muscle ActRII receptors and thereby relieving their inhibitory effects on muscle protein synthesis and satellite cell activation. By sequestering both myostatin and activin A simultaneously, follistatin-344 neutralizes two complementary negative regulators of muscle growth through a dual-pathway mechanism, a property that distinguishes it from agents that target only the myostatin pathway. Transgenic expression of human follistatin-344 has produced significant skeletal muscle mass increases in animal models, and a phase 1/2a gene therapy trial delivering the follistatin-344 gene via AAV to patients with Becker muscular dystrophy established initial proof of concept and safety data in a human clinical context. Follistatin-344 has not received FDA approval for any indication; exogenous administration as a recombinant protein or peptide is investigational and no human safety data exists for this route of administration outside gene therapy trial contexts. Follistatin-344 as a research compound: recombinant follistatin-344 protein is available through research biochemical suppliers as a laboratory reagent, used in cell culture and animal models to probe myostatin and activin A biology. Interest in exogenous follistatin-344 administration in performance contexts has grown from the animal model hypertrophy data; however, the protein's large molecular weight (~35 kDa glycoprotein) creates significant bioavailability challenges for subcutaneous or intramuscular routes, and no human pharmacokinetic data supports assumed tissue distribution from injection. This distinguishes it from smaller peptide-based myostatin modulators. Follistatin-344 vs myostatin propeptide: both target myostatin inhibition but through different binding mechanisms. Follistatin-344 binds activin A in addition to myostatin, providing a broader TGF-β inhibition profile. Myostatin propeptide is the endogenous inhibitory domain of the myostatin precursor protein — it is myostatin-specific but structurally derived from the same protein rather than from a binding antagonist class. Both compounds remain at the research stage for performance applications with no approved human use. Providers offering research peptides in the performance and muscle recovery category are listed in the PeptideBase directory.

Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake. Much shorter half-life (~15 min) than the LR3 analog (~20-30 hr) due to binding protein interactions.

IGF-1 (insulin-like growth factor 1; somatomedin C) is an endogenous 70-amino-acid polypeptide produced primarily in the liver in response to growth hormone signaling, functioning as the principal mediator of GH anabolic effects through its receptor (IGF-1R) expressed in virtually all tissues, with roles in muscle protein synthesis, bone growth, and cellular proliferation. IGF-1 activates IGF-1R tyrosine kinase to stimulate PI3K/Akt and MAPK/ERK signaling cascades, promoting protein synthesis, cell survival, and glucose uptake in muscle and bone; endogenous IGF-1 levels peak during puberty and decline with age, and GH-stimulating interventions exert many of their effects by elevating circulating IGF-1. The FDA-approved recombinant form, mecasermin (Increlex), is indicated for primary IGF-1 deficiency in children with GH receptor insensitivity syndrome, with multicenter controlled clinical trials demonstrating significant height velocity improvements in this rare pediatric population; this approved indication is specific to a defined hormonal insufficiency condition and is distinct from performance-enhancing or anti-aging uses of exogenous IGF-1. Research-grade IGF-1 is available as a compounded or gray-market compound used outside its approved indication; it is not approved for adult use or performance applications, and risks associated with IGF-1 excess — including effects on glucose homeostasis, potential oncogenic cell signaling, and acromegaly-related comorbidities — are relevant safety considerations for any off-label use.